| Literature DB >> 36005130 |
Vladimir Đorđević1, Milan Petković2, Jelena Živković3, Goran M Nikolić3, Aleksandar M Veselinović3.
Abstract
For the development of atypical antipsychotics, the selective positive allosteric modulation of the ionotropic GABAA receptor (GABAAR) has emerged as a promising approach. In the presented research, two unrelated methods were used for the development of QSAR models for selective positive allosteric modulation of 1-containing GABAARs with derivatives of imidazo [1,2-a]-pyridine. The development of conformation-independent QSAR models, based on descriptors derived from local molecular graph invariants and SMILES notation, was achieved with the Monte Carlo optimization method. From the vast pool of 0D, 1D, and 2D molecule descriptors, the GA-MLR method developed additional QSAR models. Various statistical methods were utilised for the determination of the developed models' robustness, predictability, and overall quality, and according to the obtained results, all QSAR models are considered good. The molecular fragments that have a positive or negative impact on the studied activity were obtained from the studied molecules' SMILES notations, and according to the obtained results, nine novel compounds were designed. The binding affinities to GABAAR of designed compounds were assessed with the application of molecular docking studies and the obtained results showed a high correlation with results obtained from QSAR modeling. To assess all designed molecules' "drug-likeness", their physicochemical descriptors were computed and utilised for the prediction of medicinal chemistry friendliness, pharmacokinetic properties, ADME parameters, and druglike nature.Entities:
Keywords: GABAA receptor; QSAR; drug design; molecular modeling; schizophrenia
Year: 2022 PMID: 36005130 PMCID: PMC9406691 DOI: 10.3390/cimb44080234
Source DB: PubMed Journal: Curr Issues Mol Biol ISSN: 1467-3037 Impact factor: 2.976
Figure 1General chemical structure of studied molecules.
The statistical quality of QSAR models developed with the Monte Carlo optimization method for selective positive allosteric modulation of α1-containing GABAARs.
| Run | Training Set | Test Set | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r2 | CCC | IIC | q2 | s | MAE | F | r2 | CCC | IIC | q2 | s | MAE | F | ||
| Split 1 | 1 | 0.8553 | 0.922 | 0.7267 | 0.8288 | 0.166 | 0.116 | 136 | 0.8468 | 0.9192 | 0.9202 | 0.7767 | 0.207 | 0.163 | 33 |
| 2 | 0.8302 | 0.9073 | 0.7159 | 0.8059 | 0.180 | 0.127 | 112 | 0.8586 | 0.9164 | 0.9266 | 0.7872 | 0.194 | 0.152 | 36 | |
| 3 | 0.8413 | 0.9138 | 0.8467 | 0.8104 | 0.174 | 0.118 | 122 | 0.8355 | 0.9141 | 0.9140 | 0.7468 | 0.209 | 0.163 | 30 | |
| Av | 0.8423 | 0.9144 | 0.7631 | 0.8150 | 0.173 | 0.120 | 123 | 0.8470 | 0.9166 | 0.9203 | 0.7702 | 0.203 | 0.159 | 33 | |
| Split 2 | 1 | 0.8518 | 0.9200 | 0.7252 | 0.8296 | 0.179 | 0.139 | 132 | 0.8523 | 0.9086 | 0.9225 | 0.6671 | 0.181 | 0.138 | 35 |
| 2 | 0.8219 | 0.9023 | 0.8369 | 0.7888 | 0.196 | 0.159 | 106 | 0.8419 | 0.9123 | 0.9175 | 0.6644 | 0.164 | 0.114 | 32 | |
| 3 | 0.8483 | 0.9179 | 0.6140 | 0.8223 | 0.181 | 0.147 | 129 | 0.8371 | 0.9118 | 0.9145 | 0.6309 | 0.171 | 0.117 | 31 | |
| Av | 0.8407 | 0.9134 | 0.7254 | 0.8136 | 0.185 | 0.148 | 122 | 0.8438 | 0.9109 | 0.9182 | 0.6541 | 0.172 | 0.123 | 33 | |
| Split 3 | 1 | 0.8411 | 0.9137 | 0.6114 | 0.8178 | 0.182 | 0.143 | 122 | 0.9479 | 0.9678 | 0.9735 | 0.8732 | 0.103 | 0.070 | 109 |
| 2 | 0.8528 | 0.9205 | 0.6157 | 0.8283 | 0.175 | 0.132 | 133 | 0.9164 | 0.9456 | 0.9573 | 0.7794 | 0.145 | 0.121 | 66 | |
| 3 | 0.8557 | 0.9223 | 0.8539 | 0.8365 | 0.174 | 0.140 | 136 | 0.9121 | 0.9530 | 0.9540 | 0.8476 | 0.131 | 0.104 | 62 | |
| Av | 0.8499 | 0.9880 | 0.6937 | 0.8275 | 0.177 | 0.138 | 130 | 0.9255 | 9.5555 | 0.9616 | 0.8334 | 0.126 | 0.098 | 79 | |
r2—Correlation coefficient; CCC—concordance correlation coefficient; IIC—index of ideality of correlation; q2—Cross−validated correlation coefficient; s—Standard error of estimation; MAE—Mean absolute error; F—Fischer ratio; Av—Average value for statistical parameters obtained from three independent Monte Carlo optimization runs.
Figure 2(Above): graphical representation of the best Monte Carlo optimization runs (the highest value for the r2) for the developed QSAR models; (Below): difference between experimental and calculated values for pKi.
The example of DCW(3,7) calculation.
|
|
|
|
|
|
|
|
|
| F........... | 0.0034 | 1........... | 0.0539 | c...(....... | 0.4537 | (...N...(... | 0.0812 |
| c........... | 0.0736 | c........... | 0.0736 | c...(....... | 0.4537 | N...(...C... | 1.0483 |
| 1........... | 0.0539 | c........... | 0.0736 | n...(....... | 0.5428 | (...C...(... | −0.5696 |
| c........... | 0.0736 | c........... | 0.0736 | n...2....... | 0.2752 | C...(...C... | 0.8183 |
| c........... | 0.0736 | c........... | 0.0736 | 2...(....... | 0.8207 | (...C...(... | −0.5696 |
| c........... | 0.0736 | c........... | 0.0736 | c...(....... | 0.4537 | c...(...C... | −0.4617 |
| 2........... | 4.4302 | 1........... | 0.0539 | c...1....... | 0.0753 | (...c...(... | 2.227 |
| n........... | 1.3439 | c...F....... | 0.2931 | c...1....... | 0.0753 | n...(...c... | 0.3335 |
| (........... | −0.9688 | c...1....... | 0.0753 | c...c....... | 0.3591 | 2...n...(... | −0.7845 |
| c........... | 0.0736 | c...1....... | 0.0753 | c...c....... | 0.3591 | n...2...(... | 0.0209 |
| 1........... | 0.0539 | c...c....... | 0.3591 | c...c....... | 0.3591 | c...(...2... | 0.3706 |
| (........... | −0.9688 | c...c....... | 0.3591 | c...c....... | 0.3591 | 1...c...(... | 1.2055 |
| c........... | 0.0736 | c...2....... | −0.5812 | c...1....... | 0.0753 | c...1...c... | 0.4915 |
| (........... | −0.9688 | n...2....... | 0.2752 | F...c...1... | −0.2005 | c...c...1... | 1.4286 |
| C........... | −0.116 | n...(....... | 0.5428 | c...1...c... | 0.4915 | c...c...c... | 0.7319 |
| C........... | −0.116 | c...(....... | 0.4537 | c...c...1... | 1.4286 | c...c...c... | 0.7319 |
| (........... | −0.9688 | c...1....... | 0.0753 | c...c...c... | 0.7319 | c...c...c... | 0.7319 |
| =........... | 1.1592 | 1...(....... | 0.3914 | c...c...2... | 1.1064 | c...c...1... | 1.4286 |
| O........... | −0.0923 | c...(....... | 0.4537 | n...2...c... | 0.3482 | Cmax.2...... | 0.8467 |
| (........... | −0.9688 | c...(....... | 0.4537 | 2...n...(... | −0.7845 | Nmax.1...... | 0.0445 |
| N........... | −0.0466 | C...(....... | 0.2144 | n...(...c... | 0.3335 | Omax.1...... | 0.0472 |
| (........... | −0.9688 | C...C....... | 0.0285 | 1...c...(... | 1.2055 | Smax.0...... | 2.741 |
| C........... | −0.116 | C...(....... | 0.2144 | c...1...(... | 0.0569 | NOSP11000000 | 0.0558 |
| (........... | −0.9688 | =...(....... | 2.1975 | c...(...1... | −0.1945 | HALO10000000 | 0.5334 |
| C........... | −0.116 | O... = ....... | 1.9829 | (...c...(... | 2.227 | BOND10000000 | −0.2316 |
| (........... | −0.9688 | O...(....... | 2.1172 | c...(...C... | −0.4617 | ++++F−−−N=== | 0.6827 |
| c........... | 0.0736 | N...(....... | 0.0575 | C...C...(... | 0.0563 | ++++F−−−O=== | 0.7066 |
| (........... | −0.9688 | N...(....... | 0.0575 | C...C...(... | 0.0563 | ++++N−−−O=== | 1.2605 |
| n........... | 1.3439 | C...(....... | 0.2144 | C...(...=... | 1.221 | ++++F−−−B2== | −0.952 |
| 2........... | 4.4302 | C...(....... | 0.2144 | O...=...(... | 0.6219 | ++++O−−−B2== | 0.2153 |
| (........... | −0.9688 | C...(....... | 0.2144 | =...O...(... | 2.0622 | ++++N−−−B2== | 1.4959 |
| c........... | 0.0736 | C...(....... | 0.2144 | O...(...N... | −0.4948 | 10011001000 | 0.3564 |
Figure 3Schematics for computer—aided drug design.
The list of all designed molecules with their SMILES notation and calculated activities.
| Molecule | SMILES Notation | pKi |
|---|---|---|
| A | Fc1ccc2n(c1)c(CC(=O)N(C)C)c(n2)c1ccccc1 | 6.7559 |
| A1 | Fc1ccc2n(c1)c(CC(=O)N(C)C)c(n2)c1ccccc1C | 7.4613 |
| A2 | Fc1ccc2n(c1)c(CC(=O)N(C)C)c(n2)c1cccc(c1)C | 7.1357 |
| A3 | Cc1ccc(cc1)c1nc2n(c1CC(=O)N(C)C)cc(cc2)F | 7.5160 |
| A4 | CCc1ccccc1c1nc2n(c1CC(=O)N(C)C)cc(cc2)F | 7.1291 |
| A5 | CCc1cccc(c1)c1nc2n(c1CC(=O)N(C)C)cc(cc2)F | 7.3736 |
| A6 | CCc1ccc(cc1)c1nc2n(c1CC(=O)N(C)C)cc(cc2)F | 7.3465 |
| A7 | CCN(C(=O)Cc1c(nc2n1cc(F)cc2)c1ccccc1C(C)C)C | 8.0238 |
| A8 | Fc1ccc2n(c1)c(CC(=O)N(C)C)c(n2)c1cccc(c1)C(C)C | 7.7217 |
| A9 | Fc1ccc2n(c1)c(CC(=O)N(C)C)c(n2)c1ccc(cc1)C(C)C | 7.6353 |
Score values (kcal/mol) for all computer−aided designed compounds.
| Molecule | Steric | VdW | HBond | NoHBond90 | Energy | MolDock | Rerank |
|---|---|---|---|---|---|---|---|
| A | −140.362 | −46.2960 | −6.23697 | −6.65395 | −141.363 | −139.441 | −117.842 |
| A1 | −145.212 | −12.2465 | −3.76233 | −4.03557 | −145.993 | −137.563 | −86.1434 |
| A2 | −145.305 | −44.9493 | −6.96824 | −7.94622 | −148.877 | −146.146 | −121.477 |
| A3 | −140.519 | −42.7464 | −6.89116 | −7.66588 | −143.953 | −140.793 | −117.046 |
| A4 | −151.161 | −42.7453 | −2.49702 | −2.50000 | −145.106 | −143.846 | −115.584 |
| A5 | −151.189 | −46.0394 | −3.74132 | −4.28093 | −152.537 | −151.130 | −120.893 |
| A6 | −150.538 | −21.8530 | −4.48654 | −6.94755 | −146.135 | −146.097 | −108.561 |
| A7 | −148.919 | −26.6788 | −7.14605 | −7.95491 | −152.918 | −153.347 | −117.813 |
| A8 | −157.365 | −39.4826 | −2.50000 | −2.50000 | −154.518 | −150.102 | −110.772 |
| A9 | −151.100 | −17.1298 | −4.53151 | −7.03151 | −146.090 | −148.784 | −105.663 |
Figure 4(A) Best calculated poses for all designed molecules inside the active site of α1-containing GABAARs; (B) Aromatic interactions inside active site; (C) Hydrogen bonds related interactions inside active site; (D) Hydrophobic interactions inside active site.
Figure 5BOILED−Egg diagram for all designed molecules (BBB—Blood–brain barrier; PG+/−—P−glycoprotein; HIA—human intestinal absorption).